Skip to main content
See every side of every news story
Published • loading... • Updated

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

  • Zhejiang Wenda Pharmaceutical Technology Co., Ltd. will present Phase II data for oral BET inhibitor NHWD-870 HCl in Chinese patients with advanced NUT carcinoma at the 2026 ESMO Annual Meeting.
  • In the multicenter, open-label trial, patients received 2 mg of NHWD-870 HCl orally for five days, followed by two days off, in 28-day cycles.
  • An independent review found an objective response rate of 30.0% and a disease control rate of 47.5% among 40 patients.
  • Median progression-free survival was 2.76 months and overall survival was 9.33 months; the response rate among patients with primary thoracic tumors was 45.0%.
Insights by Ground AI

47 Articles

Appalachian News-ExpressAppalachian News-Express
+45 Reposted by 45 other sources
Center

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 77% of the sources are Center
77% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in Chicago, United States on Sunday, October 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal